Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 4/20 | 0.48 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.43 |
| ▸ | LIPC | P11150 | 2/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.43 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.40 |
| ▸ | CPT1A | P50416 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3220842 | 1.00 | AADAT (0.48) | AADATLIPGLIPCENPP2ATXN2 | |
| SCHEMBL14160545 | 0.89 | AADAT (0.50) | AADATLIPGLIPCCPT1A | |
| SCHEMBL14117159 | 0.87 | AADAT (0.50) | AADATMEN1KMT2ASMN1; SMN2PPARG | |
| SCHEMBL3215257 | 0.82 | ENPP2 (0.43) | AADATENPP2ATXN2MEN1NPC1 | |
| SCHEMBL3200648 | 0.82 | USP30 (0.48) | ENPP2ATXN2 | |
| SCHEMBL3215248 | 0.82 | ENPP2 (0.43) | AADATENPP2ATXN2MEN1NPC1 | |
| SCHEMBL3200630 | 0.82 | USP30 (0.48) | ENPP2ATXN2 | |
| SCHEMBL13424945 | 0.82 | TMEM97 (0.52) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL3212933 | 0.82 | TMEM97 (0.52) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL3220048 | 0.82 | AADAT (0.48) | AADATLIPGENPP2CPT1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100055071-A1 | Anti-Viral Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-20100055071-A1 | Anti-Viral Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-20100055071-A1 | Anti-Viral Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| EP-2097405-A2 | ANTI-VIRAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20080193411-A1 | Anti-viral Compounds | GENELABS TECHNOLOGIES, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080193411-A1 | Anti-viral Compounds | GENELABS TECHNOLOGIES, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008070447-A2 | ANTI-VIRAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193411-A1 | Anti-viral Compounds | ZC3HAV1, ZC3HAV1L, SARS1 | AADAT 2338/4885LIPG 1624/4885LIPC 1753/4885 |
| US-20100055071-A1 | Anti-Viral Compounds | ZC3HAV1, ZC3HAV1L, SARS1 | AADAT 2338/4885LIPG 1624/4885LIPC 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.